Any coronavirus vaccine that could be authorized for emergency use by the U.S. Food and Drug Administration (FDA) faces several additional hurdles after completing the final stage of clinical trials.

That was the theme of key issues addressed today by the FDA’s vaccine advisory committee — which includes a group of health and science experts who advise the regulatory agency on the best way to approach the path forward for a COVID-19 vaccine.

Among the more immediate hurdles, the path to receive an emergency use authorization remains somewhat murky for the pharmaceutical industry, as the agency has not nailed down specifics for things such as labeling and what qualifies as sufficient monitoring of individuals who have enrolled in clinical trials.

Read more